Recombinant Mouse PD-1 Fc Chimera Protein, CF

When Recombinant Mouse PD-1 Fc Chimera (Catalog # 1021-PD) is coated at 1 μg/mL, Recombinant Mouse B7‑H1/PD‑L1 Fc Chimera (Catalog # 1019-B7) binds with an ED50 of 0.16-0.8 μg/mL.

• Reactivity: Mu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Mouse PD-1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Mouse PD-1 Fc Chimera at 1 µg/mL (100 µL/well) can bind Recombinant Mouse B7‑H1/PD‑L1 Fc Chimera (Catalog # 1019-B7) with an ED₅₀ of 0.16-0.8 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse PD-1 protein
  

  Mouse PD-1 (Leu25-Gln167) Accession # Q02242	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q02242
• N-terminal Sequence: Leu25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Pdcd1
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 43 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 66 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris-HCL, NaCl and EDTA with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse PD-1 Fc Chimera Protein, CF

• CD279 antigen
• CD279
• hPD-1
• PD1
• PD-1
• PD1hPD-l
• PDCD1
• programmed cell death 1
• programmed cell death protein 1
• Protein PD-1
• SLEB2

Background

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). Mature mouse PD-1 consists of a 149 amino acid (aa) extracellular region (ECD) with one immunoglobulin-like V-type domain, a 21 aa transmembrane domain, and a 98 aa cytoplasmic region. The mouse PD-1 ECD shares 65% aa sequence identity with the human PD-1 ECD. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces
co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1:PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12, 13).

1. Ishida, Y. et al. (1992) EMBO J. 11:3887.
2. Sharpe, A.H. and G. J. Freeman (2002) Nat. Rev. Immunol. 2:116.
3. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
4. Nishimura, H. and T. Honjo (2001) Trends Immunol. 22:265.
5. Watanabe, N et al. (2003) Nat. Immunol. 4:670.
6. Zhang, X. et al. (2004) Immunity 20:337.
7. Lázár-Molnár, E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:10483.
8. Nishimura, H et al. (1996) Int. Immunol. 8:773.
9. Keir, M.E. et al. (2008) Annu. Rev. Immunol. 26:677.
10. Butte, M.J. et al. (2007) Immunity 27:111.
11. Okazaki, T. et al. (2013) Nat. Immunol. 14:1212.
12. Iwai, Y. et al. (2002) Proc. Natl. Acad. Sci. USA 99: 12293.
13. Nogrady, B. (2014) Nature 513:S10.

Publications for PD-1 (1021-PD)(8)

Publications using 1021-PD

• A Mehdi, M Attias, A Arakelian, CA Piccirillo, M Szyf, SA Rabbani Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone Cancers, 2022-12-22;15(1):. 2022-12-22 [PMID: 36612044] (Bioassay, Mouse)
• CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, P Hayes, S Stelter, PD Bartlett, M Zuazo, MJ Garcia-Gra, G Benedetti, S Fiaska, NR Birkett, Y Teng, C Enever, H Arasanz, A Bocanegra, L Chocarro, G Fernandez, R Vera, B Archer, I Osuch, M Lewandowsk, YM Surani, G Kochan, D Escors, J Legg, AJ Pierce The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity British Journal of Cancer, 2021-12-30;0(0):. 2021-12-30 [PMID: 34969998] (Bioassay, Mouse)
• J Guiteras, L De Ramon, E Crespo, N Bolaños, S Barcelo-Ba, L Martinez-V, P Fontova, M Jarque, A Torija, O Bestard, D Resina, JM Grinyó, J Torras Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models International Journal of Molecular Sciences, 2021-01-26;22(3):. 2021-01-26 [PMID: 33530581] (Surface Plasmon Resonance, Rat)
• N Silva-Pili, E Martisova, MC Ballestero, S Hervas-Stu, N Casares, G González-S, C Smerdou, L Vanrell Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity Biomedicines, 2020-12-02;8(12):. 2020-12-02 [PMID: 33276580] (Bioassay, ELISA Capture, Human)
• L Jacobs, E De Smidt, N Geukens, P Declerck, K Hollevoet DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure Mol. Ther., 2020-02-13;0(0):. 2020-02-13 [PMID: 32101701] (ELISA Standard, Mouse)
• Matsumura , Takuhiro, Sugawara , Yo, Yutani , Masahiro, Amatsu , Sho, Yagita , Hideo, Kohda , Tomoko, Fukuoka , Shin-Ich, Nakamura , Yutaka, Fukuda , Shinji, Hase , Koji, Ohno , Hiroshi, Fujinaga , Yukako Botulinum toxin A complex exploits intestinal M cells to enter the host and exert neurotoxicity. Nat Commun, 2015-02-17;6(0):6255. 2015-02-17 [PMID: 25687350] (Enzyme Assay, Mouse)
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 2007-07-12;27(1):111-22. 2007-07-12 [PMID: 17629517] (Bioassay, Mouse)
• Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J. Immunol., 2007-02-01;178(3):1523-33. 2007-02-01 [PMID: 17237401] (Flow Cytometry, Mouse)

Bioinformatics

• Gene Symbol: Pdcd1
• Uniprot:
  • Q02242()